TP53 and B-cell chronic lymphocytic leukemia: Using a range of B cell lines and primary CLL samples with different TP53 statuses, we found that HDM201 effectively targets TP53 wild-type and heterozygous TP53-KO cells but shows limited efficacy in TP53 mutant and homozygous TP53-KO cells.